Arthur He
Stock Analyst at HC Wainwright & Co.
(1.07)
# 3,331
Out of 4,670 analysts
59
Total ratings
27.59%
Success rate
-11.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAP Adaptimmune Therapeutics | Reiterates: Buy | $3.5 | $0.66 | +429.02% | 5 | Nov 19, 2024 | |
| PSTX Poseida Therapeutics | Reiterates: Buy | $20 | $2.73 | +632.60% | 16 | Nov 15, 2024 | |
| BCAB BioAtla | Downgrades: Neutral | n/a | $1.57 | - | 7 | Nov 13, 2024 | |
| PRME Prime Medicine | Reiterates: Buy | $10 | $3.20 | +212.50% | 5 | Nov 13, 2024 | |
| SLDB Solid Biosciences | Reiterates: Buy | $16 | $5.41 | +195.75% | 5 | Nov 7, 2024 | |
| ADAG Adagene | Reiterates: Buy | $5 | $2.19 | +127.95% | 8 | Sep 18, 2024 | |
| LVTX LAVA Therapeutics | Reiterates: Buy | $6 | $1.60 | +275.00% | 7 | Jun 28, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Buy | $50 → $60 | $2.15 | +2,690.70% | 6 | Jun 5, 2024 |
Adaptimmune Therapeutics
Nov 19, 2024
Reiterates: Buy
Price Target: $3.5
Current: $0.66
Upside: +429.02%
Poseida Therapeutics
Nov 15, 2024
Reiterates: Buy
Price Target: $20
Current: $2.73
Upside: +632.60%
BioAtla
Nov 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.57
Upside: -
Prime Medicine
Nov 13, 2024
Reiterates: Buy
Price Target: $10
Current: $3.20
Upside: +212.50%
Solid Biosciences
Nov 7, 2024
Reiterates: Buy
Price Target: $16
Current: $5.41
Upside: +195.75%
Adagene
Sep 18, 2024
Reiterates: Buy
Price Target: $5
Current: $2.19
Upside: +127.95%
LAVA Therapeutics
Jun 28, 2024
Reiterates: Buy
Price Target: $6
Current: $1.60
Upside: +275.00%
HOOKIPA Pharma
Jun 5, 2024
Maintains: Buy
Price Target: $50 → $60
Current: $2.15
Upside: +2,690.70%